Descripción de la empresa
Cumberland Pharmaceuticals Inc. operates as a specialty pharmaceutical entity dedicated to the strategic acquisition, development, and commercialization of prescription therapeutic products designed to address specific medical needs. The company functions within the Healthcare sector, specifically targeting the Drug Manufacturers - Specialty & Generic industry, which focuses on producing specialized medications often for niche patient populations or complex conditions. As of the latest reporting period, the entity maintains a market capitalization of $45.92M and employs a workforce of 93 individuals to support its operational and commercial objectives. These financial dimensions indicate that Cumberland Pharmaceuticals is a small-cap organization with limited revenue generation relative to large-cap peers, suggesting a business model reliant on high-value, specialized product lines rather than broad-based volume sales.
Salud financiera
The company reported a total revenue of $44.52M over the trailing twelve months, yet it recorded a net income of $-2,836,128, highlighting a significant disparity between top-line growth and bottom-line profitability that points to substantial operating costs or non-operating expenses eroding earnings. Despite the negative net income, the firm generated an EBITDA of $1.35M, which serves as a critical indicator of its operational cash generation capability before interest, taxes, depreciation, and amortization. The business demonstrated strong liquidity with free cash flow reaching $6.44M, providing the financial flexibility to fund ongoing research, development activities, or potential strategic acquisitions without relying solely on external financing. Profitability metrics reveal a gross margin of 85.0%, indicating efficient production costs and high value capture per unit sold, while the operating margin stands at -10.0% and the profit margin at -6.4%, reflecting the heavy investment phase or high fixed cost structure typical of specialty drug manufacturers. On the balance sheet, the company holds $11.44M in cash against $10.18M in debt, resulting in a debt-to-equity ratio of 41.48, which suggests a leveraged capital structure where equity is a smaller base relative to the debt load. Short-term liquidity appears tight with a current ratio of 1.01, meaning current assets barely exceed current liabilities, which requires careful cash management to meet immediate obligations. Return on Equity is negative at -12.2% and Return on Assets is -2.3%, metrics that collectively reveal that management is currently not generating positive returns on the capital invested in the business, a common characteristic for companies scaling up their product portfolios.
Evaluación de valoración
Valuation multiples present a mixed picture where the trailing P/E ratio is not available due to losses, while the forward P/E is projected at 21.93, implying that the market expects significant earnings recovery or stabilization in the coming year to justify the current share price. The price-to-book ratio is 1.85, suggesting that the market values the company at a premium of 85% over its net asset value, potentially reflecting the intangible value of its proprietary drug pipelines and future revenue potential. Alternative valuation measures include a price-to-sales ratio of 1.03 and an EV/EBITDA of 32.75, which provide context for investors evaluating the company's worth relative to its sales volume and enterprise value-adjusted earnings power. The stock has exhibited significant volatility within its trading range, with a 52-week high of $6.27 and a 52-week low of $1.85, indicating that the current price point is subject to substantial fluctuation based on sector sentiment and company-specific developments. The beta value of -0.33 is an anomalous metric that suggests the stock price moves inversely to the broader market or exhibits extreme volatility patterns that differ from standard equity behavior, warranting close monitoring for risk-averse investors.
Growth & Income
Revenue growth accelerated significantly with a year-over-year increase of 31.1%, driven likely by the commercialization of key products like Acetadote and Caldolor, whereas earnings growth is not applicable due to the current net loss position, indicating that top-line expansion has not yet translated into profitability. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is retained within the business to fund operations and growth initiatives rather than being returned to shareholders. This reinvestment strategy is consistent with the company's stage of development, where preserving capital is essential to sustain the high margins required to eventually achieve positive net income. Consequently, the overall growth and income profile is characterized by robust top-line expansion paired with a complete lack of current income generation, positioning Cumberland Pharmaceuticals as a pure-play growth asset for investors seeking exposure to specialty pharmaceutical development without dividend reliance.